Meptazinol

Jump to: navigation, search
Meptazinol
Meptazinol.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Dependence
liability
Low
Routes of
administration
Oral, IM, IV
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
Pharmacokinetic data
MetabolismThe peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours.
Elimination half-lifeHalf-Life (1.4–4 hours).
ExcretionThe drug is rapidly metabolised to the glucuronide, and mostly excreted in the urine.
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H23NO
Molar mass233.34922 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Meptazinol

Articles

Most recent articles on Meptazinol

Most cited articles on Meptazinol

Review articles on Meptazinol

Articles on Meptazinol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Meptazinol

Images of Meptazinol

Photos of Meptazinol

Podcasts & MP3s on Meptazinol

Videos on Meptazinol

Evidence Based Medicine

Cochrane Collaboration on Meptazinol

Bandolier on Meptazinol

TRIP on Meptazinol

Clinical Trials

Ongoing Trials on Meptazinol at Clinical Trials.gov

Trial results on Meptazinol

Clinical Trials on Meptazinol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Meptazinol

NICE Guidance on Meptazinol

NHS PRODIGY Guidance

FDA on Meptazinol

CDC on Meptazinol

Books

Books on Meptazinol

News

Meptazinol in the news

Be alerted to news on Meptazinol

News trends on Meptazinol

Commentary

Blogs on Meptazinol

Definitions

Definitions of Meptazinol

Patient Resources / Community

Patient resources on Meptazinol

Discussion groups on Meptazinol

Patient Handouts on Meptazinol

Directions to Hospitals Treating Meptazinol

Risk calculators and risk factors for Meptazinol

Healthcare Provider Resources

Symptoms of Meptazinol

Causes & Risk Factors for Meptazinol

Diagnostic studies for Meptazinol

Treatment of Meptazinol

Continuing Medical Education (CME)

CME Programs on Meptazinol

International

Meptazinol en Espanol

Meptazinol en Francais

Business

Meptazinol in the Marketplace

Patents on Meptazinol

Experimental / Informatics

List of terms related to Meptazinol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Meptazinol (trade name Meptid) is an opioid analgesic developed by Wyeth in the 1970s. Indications for use in moderate to severe pain, most commonly used to treat pain in obstetrics (childbirth). A partial µ-opioid receptor agonist, its mixed agonist/antagonist activity affords it a lower risk of dependence and abuse than full µ agonists like morphine. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other opioids such as morphine, pentazocine, or buprenorphine.

It does not appear in the US Controlled Substances Act 1970; it may or may not be regulated as an analogue of controlled relatives such as proheptazine (ACSCN 9643)

References


Linked-in.jpg